Safety and Pilot Efficacy of AKB-9778 in Subjects With Diabetic Macular Edema

Summary

The purpose of this study is to evaluate the safety, pharmacokinetics, pharmacodynamics, and pilot efficacy of multiple ascending dose levels of AKB-9778 given as subcutaneous injections daily for 28 days in patients with diabetic macular edema (DME).

Timeline

Start

2012-09

Primary completion

2013-09

Completion

2014-12

Drugs

Indications